Skandinaviska Enskilda Banken (SEB)
ADMA icon

Skandinaviska Enskilda Banken (SEB)’s ADMA Biologics ADMA Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,269
Closed -$33.3K – 711
2025
Q3 		$33.3K Buy
2,269
+496
+28% +$8.5K ﹤0.01% 759
2025
Q2 		$32.3K Hold
1,773
– – ﹤0.01% 811
2025
Q1 		$35.2K Buy
+1,773
New +$30.7K ﹤0.01% 791

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.82B AUM 73.38% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s ADMA Position: Q4 2025 in Review

Skandinaviska Enskilda Banken (SEB) sold out of ADMA Biologics (ADMA) in Q4 2025, closing a stake of 2,269 shares — an estimated $33.3K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in ADMA in Q1 2025 and held it in 3 quarters. The position peaked at $35.2K in Q1 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q4 2025.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining ADMA Biologics position as of Q4 2025 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 2,269 ADMA Biologics shares in Q4 2025, an estimated $33.3K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in ADMA Biologics in Q1 2025 and held it in 3 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s ADMA Biologics position peaked at $35.2K in Q1 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2025.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q4 2025, filed 12 Feb 2026.